A novel function of membrane-associated collagen in cancer metastasis.
Authors: Zhang H, Xu R PMID: 31080548 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Coincidence detection of RAB11A and PI(3)P by WIPI2 directs autophagosome formation.
Authors: Vicinanza M, Puri C, Rubinsztein DC PMID: 31080549 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Targeting R-loop-associated ATR response in myelodysplastic syndrome.
Authors: Nguyen HD, Zou L, Graubert TA PMID: 31080550 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

A state of stochastic cancer stemness through the CDK1-SOX2 axis.
Authors: Menon DR, Fujita M Abstract The concept of cancer stemness has undergone a paradigm shift during the last decade where there is wider acceptance of the idea that stemness in cancer is a more dynamic and plastic phenomenon than previously thought. However, we have yet to understand the mechanisms on how this stochastic plasticity arises and is maintained. Recently, we have shown that CDK1 plays a critical role in stochastic stemness and tumor initiation potential through regulating SOX2 phosphorylation in multiple cancer types. The phosphorylation of SOX2 affects its nuclear localization, thereby determinin...
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Rapid activation of epithelial-mesenchymal transition drives PARP inhibitor resistance in Brca2-mutant mammary tumours.
Authors: Ordonez LD, Hay T, McEwen R, Polanska UM, Hughes A, Delpuech O, Cadogan E, Powell S, Dry J, Tornillo G, Silcock L, Leo E, O'Connor MJ, Clarke AR, Smalley MJ Abstract Tumours defective in the DNA homologous recombination repair pathway can be effectively treated with poly (ADP-ribose) polymerase (PARP) inhibitors; these have proven effective in clinical trials in patients with BRCA gene function-defective cancers. However, resistance observed in both pre-clinical and clinical studies is likely to impact on this treatment strategy. Over-expression of phosphoglycoprotein (P-gp) has been previously suggested a...
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Driver genes exome sequencing reveals distinct variants in African Americans with colorectal neoplasia.
Conclusion: We here report the specifics of variants' profiles of African Americans with colorectal lesions. Validated variants showed that Tumor Suppressor Genes (TSGs) APC and ARID1 and DNA Mismatch repair (MMR) genes MSH3 and MSH6 are the genes with the highest numbers of validated variants. Oncogenes KRAS and PIK3CA are also altered and likely participate in the increased proliferative potential of the mutated colonic epithelial cells in this population. PMID: 31080553 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Low dose photodynamic therapy harmonizes with radiation therapy to induce beneficial effects on pancreatic heterocellular spheroids.
In conclusion, the beneficial RT/PDT treatment outcomes encourage the further development of nanoscinitillators for X-ray-activated PDT. Assessment of such combination treatments should encompass multiparametric and temporally-spaced assessment of treatment effects in preclinical cancer models. PMID: 31080554 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

MicroRNA profiling of pancreatic ductal adenocarcinoma (PDAC) reveals signature expression related to lymph node metastasis.
Authors: Lemberger M, Loewenstein S, Lubezky N, Nizri E, Pasmanik-Chor M, Barazovsky E, Klausner JM, Lahat G Abstract Lymph node (LN) metastasis occurs frequently in pancreatic ductal adenocarcinoma (PDAC), representing an advanced disease stage and independently predicting patient survival. Current nodal staging is inadequate preoperatively and even less so postoperatively, and molecular biomarkers are needed to improve prognostication and selection of therapy. Recent data have suggested important roles of miRNAs in PDAC tumorigenesis and progression. The aim of the present study was to identify miRNA expression s...
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Correction: Reduced E-cadherin expression is correlated with poor prognosis in patients with bladder cancer: a systematic review and meta-analysis.
Authors: Xie Y, Li P, Gao Y, Gu L, Chen L, Fan Y, Zhang F, Zhang X Abstract [This corrects the article DOI: 10.18632/oncotarget.19934.]. PMID: 31080556 [PubMed - in process] (Source: Oncotarget)
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Phase I/Ib study of olaparib and carboplatin in heavily pretreated recurrent high-grade serous ovarian cancer at low genetic risk.
Conclusions: The olaparib and carboplatin combination is tolerable and has clinical benefit in subsets of heavily pretreated BRCAwt HGSOC, independent of platinum sensitivity. PMID: 31080557 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Efficient delivery of small interfering RNAs targeting particular mRNAs into pancreatic cancer cells inhibits invasiveness and metastasis of pancreatic tumors.
We report the use of small interfering RNAs (siRNAs) against ARHGEF4, CCDC88A, LAMTOR2, mTOR, NUP85, and WASF2 and folic acid (FA)-modified polyethylene glycol (PEG)-chitosan oligosaccharide lactate (COL) nanoparticles for targeting, imaging, delivery, gene silencing, and inhibition of invasiveness and metastasis in an orthotopic xenograft model. In vitro assays revealed that these siRNA-FA-PEG-COL nanoparticles were specifically inserted into pancreatic cancer cells compared to immortalized normal pancreatic epithelial cells and knocked down expression of the corresponding targets in pancreatic cancer cells. Cell motility...
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Axl signaling is an important mediator of tumor angiogenesis.
Authors: Tanaka M, Siemann DW Abstract The growth of primary tumors as well as metastatic neoplastic lesions is strongly dependent on the cancer cells' ability to initiate their own vascular network. This process, angiogenesis, which involves the proliferation, migration, and invasion of endothelial cells, is critically dependent on a variety of signaling molecules that target specific receptors, most notably tyrosine kinases. One receptor tyrosine kinase associated with poor prognosis, metastasis, and outcome in a variety of tumor types, is Axl. Although the role of Axl in tumor cell migration and invasion are wel...
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Hyper-O-GlcNAcylation promotes epithelial-mesenchymal transition in endometrial cancer cells.
This study investigated the alteration of cellular O-GlcNAcylation of proteins as the potential mechanistic connection between these two conditions. The endometrial cancer cell line (Ishikawa) was utilized to study the effect of dysregulation of O-GlcNAcylation on epithelial mesenchymal transition (EMT). Hyper-O-GlcNAcylation (via 1 μM Thiamet-G/ThmG or 25 mM Glucose) enhanced the expression of EMT-associated genes (WNT5B and FOXC2), and protein expression of the EMT adhesion molecule, N-Cadherin. Reorganization of stress filaments (actin filaments), consistent with EMT, was also noted in ThmG-treated cells. Interesting...
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patients.
Authors: Castellanos-Rizaldos E, Zhang X, Tadigotla VR, Grimm DG, Karlovich C, Raez LE, Skog JK Abstract Non-small cell lung cancer (NSCLC) is the most prevalent form of lung cancer and its molecular landscape has been extensively studied. The most common genetic alterations in NSCLC are mutations within the epidermal growth factor receptor (EGFR) gene, with frequencies between 10-40%. There are several molecular targeted therapies for patients harboring these mutations. Liquid biopsies constitute a flexible approach to monitor these mutations in real time as opposed to tissue biopsies that represent a single snap-...
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Intrinsic factor recognition promotes T helper 17/T helper 1 autoimmune gastric inflammation in patients with pernicious anemia.
Authors: Troilo A, Grassi A, Petrone L, Cianchi F, Benagiano M, Bella CD, Capitani N, Bitetti J, D'Elios S, Tapinassi S, Azzurri A, Alnwaisri H, Romagnoli J, Bizzaro N, Bergman M, Baldari CT, D'Elios MM Abstract The intrinsic factor is the major humoral autoantigen in pernicious anemia/autoimmune gastritis. Although many studies have examined the autoantibody response to intrinsic factor and H+,K+-ATPase, no information is available on possible pathogenic mechanisms mediated by intrinsic factor - specific gastric T cells. Aim of this study was to investigate intrinsic factor-specific T cells in the gastric mucosa o...
Source: Oncotarget - May 15, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Guidelines and tumor boards are required for solid organ recipients with de novo carcinoma.
Authors: Rousseau B, Guillemin A, Tournigand C PMID: 31073369 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 12, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Bevacizumab as maintenance therapy in mCRC: Interpreting results of the MOMA trial.
Authors: Marmorino F, Falcone A, Cremolini C PMID: 31073370 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 12, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

PIM kinase inhibitor, AZD1208, inhibits protein translation and induces autophagy in primary chronic lymphocytic leukemia cells.
Authors: Cervantes-Gomez F, Stellrecht CM, Ayres ML, Keating MJ, Wierda WG, Gandhi V Abstract The PIM1, PIM2, and PIM3 serine/threonine kinases play a role in the proliferation and survival of cancer cells. Mice lacking these three kinases were viable. Further, in human hematological malignancies, these proteins are overexpressed making them suitable targets. Several small molecule inhibitors against this enzyme were synthesized and tested. AZD1208, an orally available small-molecule drug, inhibits all three PIM kinases at a low nanomolar range. AZD1208 has been tested in clinical trials for patients with solid tum...
Source: Oncotarget - May 12, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Tumor-infiltrating mucosal-associated invariant T (MAIT) cells retain expression of cytotoxic effector molecules.
Authors: Sundström P, Szeponik L, Ahlmanner F, Sundquist M, Wong JSB, Lindskog EB, Gustafsson B, Quiding-Järbrink M Abstract Mucosal-associated invariant T (MAIT) cells all express a semi-invariable T cell receptor recognizing microbial metabolites presented on the MHC class I-like molecule MR1. Upon activation, they rapidly secrete cytokines and increase their cytotoxic potential. We showed recently that MAIT cells with Th1 phenotype accumulate in human colon adenocarcinomas. Here, we investigated the cytotoxic potential of tumor-infiltrating MAIT cells in colon adenocarcinomas, and to what extent it may...
Source: Oncotarget - May 12, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

The glutamate release inhibitor riluzole increases DNA damage and enhances cytotoxicity in human glioma cells, in vitro and in vivo.
Conclusions: We have demonstrated that pretreatment with the glutamate-release inhibitor riluzole sensitizes glioma cells to radiation and leads to greater cytotoxicity; these results have clinical implications for patients with glioblastoma. PMID: 31073373 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 12, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes.
Authors: Simile MM, Peitta G, Tomasi ML, Brozzetti S, Feo CF, Porcu A, Cigliano A, Calvisi DF, Feo F, Pascale RM Abstract Hepatocellular carcinoma (HCC) is characterized by the down-regulation of the liver-specific methyladenosyltransferase 1A (MAT1A) gene, encoding the S-adenosylmethionine synthesizing isozymes MATI/III, and the up-regulation of the widely expressed methyladenosyltransferase 2A (MAT2A), encoding MATII isozyme, and methyladenosyltransferase 2B (MAT2B), encoding a β-subunit without catalytic action that regulates MATII enzymatic activity. Different observations showed hepatocarcinogenesis inhib...
Source: Oncotarget - May 12, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

New mechanistic insights into modifiable risk factors that promote pancreatic cancer.
Authors: Srinivasan S, Dosch AR, Nagathihalli NS PMID: 31069003 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 11, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Do tumor cells escape from natural killer cell cytotoxicity by mimicking dendritic cells?
Authors: Wurzer H, Al Absi A, Hoffmann C, Thomas C PMID: 31069004 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 11, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

BRCAness in prostate cancer.
Authors: Bednarz-Knoll N, Eltze E, Semjonow A, Brandt B PMID: 31069005 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 11, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Prediction of onset of remnant gastric cancer by promoter DNA methylation of CDO1/HOPX/Reprimo/E-cadherin.
In this study, data for the methylation status of 4 methylation genes (CDO1, HOPX, Reprimo, and E-cadherin) to predict the onset of RGC are presented. Results: The 4 genes showed hypermethylation in RGC tumors in contrast to the corresponding non-cancerous mucosa tissues. The methylation level in the non-cancerous mucosa tissues of the initial surgery was obviously high in initial malignant disease for CDO1 (P = 0.0001), while in initial benign one for E-cadherin (P = 0.003). Promoter DNA methylation status in the remnant non-cancerous mucosa tissues together with the basic clinical data in turn predicted either initia...
Source: Oncotarget - May 11, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Development and characterization of a cancer cachexia model employing a rare human duodenal neuroendocrine carcinoma-originating cell line.
In conclusion, AkuNEC cells may serve as a useful model to study cachexia and D-NEC. PMID: 31069007 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 11, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

177Lu-PSMA radioligand therapy of predominant lymph node metastatic prostate cancer.
This study describes LuPRLT, either LuPSMA I&T or LuPSMA RLT-617, for 45 patients with predominant lymph node metastatic prostate cancer (LNM PC). Thirty-five patients had LNM and ten patients had LNM and one or two bone metastases. Before LuPRLT, the patients had prostate specific antigen (PSA) of median 18 µg/l (interquartile range (IQR): 3.3-39). LuPRLT was given with a cumulative injected 177Lu activity of median 14.5 GBq (IQR: 12.2-20.4). Maximum percentage decline of PSA was median 92% (IQR: 70-99). Thirty-five patients with only LNM had a better overall survival (OS) than ten patients with LNM and one or t...
Source: Oncotarget - May 11, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Sarcomas in the United States: Recent trends and a call for improved staging.
Conclusions: This comprehensive national study highlights important trends including increasing incidence, changing histologic types, and underestimation of true incidence. A large proportion of sarcomas are inadequately staged (unknown-grade 42.2%) with lack of appropriate surgical treatment. Our study highlights need for standardization of care for sarcomas. PMID: 31069009 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 11, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Plasma RANKL levels are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.
Conclusions: These findings suggest that circulating RANKL levels are not associated with breast cancer among BRCA mutation carriers. Pending validation in a larger sample, these findings suggest that RANKL is likely not a biomarker of breast cancer risk among BRCA mutation carriers. PMID: 31069010 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 11, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Rapid transitions in the standard of care for chronic lymphocytic leukemia (CLL).
Authors: Seymour EK PMID: 31069011 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 11, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

The triacylglycerol, hydroxytriolein, inhibits triple negative mammary breast cancer cell proliferation through a mechanism dependent on dihydroceramide and Akt.
Authors: Guardiola-Serrano F, Beteta-Göbel R, Rodríguez-Lorca R, Ibarguren M, López DJ, Terés S, Alonso-Sande M, Higuera M, Torres M, Busquets X, Escribá PV Abstract The plasma membrane is an attractive target for new anticancer drugs, not least because regulating its lipid structure can control multiple signaling pathways involved in cancer cell proliferation, differentiation and survival. Accordingly, the novel anticancer drug hydroxytriolein (HTO) was designed to interact with and regulate the composition and structure of the membrane, which in turn controls the interaction of am...
Source: Oncotarget - May 11, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Comparative proteomic analysis of human serum before and after liver transplantation using quantitative proteomics.
Authors: Zhang R, Ou M, Zhang Y, Yan Q, Chen H, Lai L, Li Y, Xu F, Tang D, Sun X, Dong J, Dai Y, Sui W Abstract Liver cancer is the second leading cause of cancer mortality worldwide. Safer and more effective diagnostic methods for liver cancer are desirable, and biomarkers represent a potentially alternative method for diagnosis. The present study was designed to identify liver cancer biomarkers. We quantified the changes in serum protein levels between liver transplantation and healthy (control) females using isobaric tags for relative and absolute quantitation (iTRAQ) as well as proteomic analysis. A total of 13...
Source: Oncotarget - May 11, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Large-scale in-silico identification of a tumor-specific antigen pool for targeted immunotherapy in triple-negative breast cancer.
In this study, we applied computational methods to comprehensively discover overexpressed molecular targets with high therapeutic relevance for clinical, immunotherapeutic cancer treatment in triple-negative breast cancer (TNBC). By actively modeling potential negative side effects utilizing expression data of 29 different, normal human tissues, we were able to develop a highly-specific coverage of TNBC patients with RNA targets. We identified here more than 400 potential tumor-specific antigens suitable for targeted therapy, including several already identified as potential targets for TNBC and other solid tumors. A speci...
Source: Oncotarget - May 11, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Evaluation of gilteritinib in combination with chemotherapy in preclinical models of FLT3-ITD+ acute myeloid leukemia.
Authors: Ueno Y, Mori M, Kamiyama Y, Saito R, Kaneko N, Isshiki E, Kuromitsu S, Takeuchi M Abstract Activating internal tandem duplication (ITD) and tyrosine kinase domain (TKD) point mutations in Fms-like tyrosine kinase 3 (FLT3) occur in approximately 30% of patients with acute myeloid leukemia (AML), and confer a poor prognosis with standard cytarabine/anthracycline or azacitidine-based chemotherapy regimens. Gilteritinib is a highly-specific, potent FLT3/AXL inhibitor with demonstrated activity against FLT3-ITD and FLT3-TKD mutations. Compared with salvage chemotherapy, treatment with once-daily oral gilteritin...
Source: Oncotarget - May 11, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Lung cancer stem cells and their aggressive progeny, controlled by EGFR/MIG6 inverse expression, dictate a novel NSCLC treatment approach.
Authors: Xiao Z, Sperl B, Gärtner S, Nedelko T, Stacher-Priehse E, Ullrich A, Knyazev PG Abstract The lung cancer stem cell (LuCSC) model comprises an attractive framework to explore acquired drug resistance in non-small cell lung cancer (NSCLC) treatment. Here, we used NSCLC cell line model to translate cellular heterogeneity into tractable populations to understand the origin of lung cancers and drug resistance. The epithelial LuCSCs, presumably arising from alveolar bipotent stem/progenitor cells, were lineage naïve, noninvasive, and prone to creating aggressive progeny expressing AT2/AT1 markers. LuCS...
Source: Oncotarget - May 11, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Role of surgery in gynaecological sarcomas.
Authors: Ghirardi V, Bizzarri N, Guida F, Vascone C, Costantini B, Scambia G, Fagotti A Abstract Gynaecological sarcomas account for 3-4% of all gynaecological malignancies and have a poorer prognosis compared to gynaecological carcinomas. Pivotal treatment for early-stage uterine sarcoma is represented by total hysterectomy. Whereas oophorectomy provides survival advantage in endometrial stromal sarcoma is still controversial. When the disease is confined to the uterus, systematic pelvic and para-aortic lymphadenectomy is not recommended. Removal of enlarged lymph-nodes is indicated in case of disseminated or recu...
Source: Oncotarget - May 11, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Correction: Monitoring EGFR-T790M mutation in serum/plasma for prediction of response to third-generation EGFR inhibitors in patients with lung cancer.
Authors: Morán T, Felip E, Bosch-Barrera J, de Aguirre I, Ramirez JL, Mesia C, Carcereny E, Roa D, Sais E, García Y, Blanco R, Sanchez S, Villacorta CR, Queralt C, Velarde JM, Rosell R Abstract [This corrects the article DOI: 10.18632/oncotarget.25478.]. PMID: 31069018 [PubMed - in process] (Source: Oncotarget)
Source: Oncotarget - May 11, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Prevention of therapy-related malignances in cancer survivors.
Authors: Belitsky GA, Kirsanov KI, Lesovaya EA, Yakubovskaya MG PMID: 31040903 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 3, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

When less is more: Gaining power through gene rearrangement of amplified EGFR.
Authors: Koga T, Chen CC, Furnari FB PMID: 31040904 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 3, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Microarray and pathway analysis of two COMMA-D ╬▓ derived clones reveal important differences relevant to their developmental capacity in-vivo.
In conclusion, increased expression of Cyclin D1, Id2 and Sox9 appear to be important for lobular genesis in SP3. Also, in-vivo 12 week displays increase expression of genes and pathways, involved in tumorigenesis. PMID: 31040905 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 3, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Pulsed SILAC-based proteomic analysis unveils hypoxia- and serum starvation-induced de novo protein synthesis with PHD finger protein 14 (PHF14) as a hypoxia sensitive epigenetic regulator in cell cycle progression.
Authors: Park JE, Tse SW, Xue G, Assisi C, Maqueda AS, Ramon GPX, Low JK, Kon OL, Tay CY, Tam JP, Sze SK Abstract Hypoxia is an environmental cue that is associated with multiple tumorigenic processes such as immunosuppression, angiogenesis, cancer invasion, metastasis, drug resistance, and poor clinical outcomes. When facing hypoxic stress, cells initiate several adaptive responses such as cell cycle arrest to reduce excessive oxygen consumption and co-activation of oncogenic factors. In order to identify the critical novel proteins for hypoxia responses, we used pulsed-SILAC method to trace the active cellular tr...
Source: Oncotarget - May 3, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

The BET-bromodomain inhibitor JQ1 renders neuroblastoma cells more resistant to NK cell-mediated recognition and killing by downregulating ligands for NKG2D and DNAM-1 receptors.
Authors: Veneziani I, Fruci D, Compagnone M, Pistoia V, Rossi P, Cifaldi L Abstract Low expression of ligands for NK cell-activating receptors contributes to neuroblastoma (NB) aggressiveness. Recently, we demonstrated that the expression of MYCN, a poor prognosis marker in NB, inversely correlates with that of activating ligands. This indicates that MYCN expression level can predict the susceptibility of NB cells to NK cell-mediated immunotherapy and that its downregulation can be exploited as a novel therapeutic strategy to induce the expression of activating ligands. Here we evaluated the effect of the BET-bromo...
Source: Oncotarget - May 3, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Phospholipid profiles and hepatocellular carcinoma risk and prognosis in cirrhotic patients.
Conclusion: This study identified phospholipid profiles related to HCC risk in liver cirrhotic patients and showed for the first time the potential of some phospholipids in predicting HCC patient mortality. PMID: 31040908 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 3, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Regulation of Kr ├╝ppel-Like Factor 4 (KLF4) expression through the transcription factor Yin-Yang 1 (YY1) in non-Hodgkin B-cell lymphoma.
Regulation of Krüppel-Like Factor 4 (KLF4) expression through the transcription factor Yin-Yang 1 (YY1) in non-Hodgkin B-cell lymphoma. Oncotarget. 2019 Mar 15;10(22):2173-2188 Authors: Morales-Martinez M, Valencia-Hipolito A, Vega GG, Neri N, Nambo MJ, Alvarado I, Cuadra I, Duran-Padilla MA, Martinez-Maza O, Huerta-Yepez S, Vega MI Abstract Krüppel-Like Factor 4 (KLF4) is a member of the KLF transcription factor family, and evidence suggests that KLF4 is either an oncogene or a tumor suppressor. The regulatory mechanism underlying KLF4 expression in cancer, and specifically in lymphoma, is s...
Source: Oncotarget - May 3, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Targeting claudin-4 enhances CDDP-chemosensitivity in gastric cancer.
Authors: Nishiguchi Y, Fujiwara-Tani R, Sasaki T, Luo Y, Ohmori H, Kishi S, Mori S, Goto K, Yasui W, Sho M, Kuniyasu H Abstract Claudins are major tight-junction proteins that mediate cellular polarity and differentiation. The present study investigated whether the 4D3 antibody to the human CLDN4 extracellular domain (that we previously established) is capable of modulating chemotherapeutic sensitivity in gastric cancer (GC). The results of the present study showed that CLDN4 was overexpressed in 137 of the 192 analyzed GC cases, and that CLDN4 expression was retained in tumors of a lower histological grade (more d...
Source: Oncotarget - May 3, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Diagnosis of peri-prosthetic loosening of total hip and knee arthroplasty using 18F-Fluoride PET/CT.
The objective of this study was to assess 18F-Fluoride PET/CT´s sensitivity and specificity in diagnosing periprosthetic loosening in total hip and knee arthroplasty. We included 26 patients with 24 hip and 13 knee prostheses in our retrospective study with radiological or clinical suspicion of peri-prosthetic loosening at least one year after implantation. Results of 18F-Fluoride PET/CT imaging were compared with surgical results or clinical follow-up if surgery was not performed. On the basis of our data we found a sensitivity of 95.00 %, a specificity of 87.04 % and an accuracy of 89.19 % for 18F-Fluoride PET/CT. ...
Source: Oncotarget - May 3, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Stratifying nonfunctional pituitary adenomas into two groups distinguished by macrophage subtypes.
Authors: Yagnik G, Rutowski MJ, Shah SS, Aghi MK Abstract Tumor-associated macrophages (TAMs) polarize to M1 and M2 subtypes exerting anti-tumoral and pro-tumoral effects, respectively. To date, little is known about TAMs, their subtypes, and their roles in non-functional pituitary adenomas (NFPAs). We performed flow cytometry on single cell suspensions from 16 NFPAs, revealing that CD11b+ myeloid cells comprise an average of 7.3% of cells in NFPAs (range = 0.5%-27.1%), with qPCR revealing most CD11b+ cells to be monocyte-derived TAMs rather than native microglia. The most CD11b-enriched NFPAs (10-27% CD11b+) were ...
Source: Oncotarget - May 3, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

The transcriptomic response to irinotecan in colon carcinoma bearing mice preconditioned by fasting.
Conclusions: Transcriptional changes after PBF to irinotecan treatment showed an improved protective stress response in healthy liver but not in tumor tissue, including changes in irinotecan metabolism. These data help to unravel the mechanisms underlying the effects of fasting on irinotecan and help to improve outcome of chemotherapeutic treatment in cancer patients. PMID: 31040913 [PubMed] (Source: Oncotarget)
Source: Oncotarget - May 3, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Correction: Allogeneic hematopoietic stem cell transplantation for relapsed acute myeloid leukemia in ETO positive with reduced-intensity conditioning.
Authors: Guo Z, Liu XD, Chen HR Abstract [This corrects the article DOI: 10.18632/oncotarget.22612.]. PMID: 31040914 [PubMed - in process] (Source: Oncotarget)
Source: Oncotarget - May 3, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research

Correction: Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.
Authors: Caroline R, Sofia G, Catherine P, Remi B, Pierre C, Olivier B, Laurent G, Valentin A, Claude C, Odile F Abstract [This corrects the article DOI: 10.18632/oncotarget.25700.]. PMID: 31040915 [PubMed - in process] (Source: Oncotarget)
Source: Oncotarget - May 3, 2019 Category: Cancer & Oncology Tags: Oncotarget Source Type: research